Special Situation Report:
Date: October 7, 2005
Newsbreak !
Quidel Corporation Receives 2005 Growth Strategy Leadership of the Year Award From Frost & Sullivan 10/6/2005 - PALO ALTO, Calif., Frost & Sullivan's recent analysis, US Rapid Microbiology Tests Markets, selected Quidel Corporation (Nasdaq: QDEL)
as the recipient of the 2005 Growth Strategy Leadership Award in the point of care (POC) diagnostic tests market. Frost & Sullivan will present Quidel
with this Award at the annual Excellence in Pharmaceuticals and Life Sciences Awards Banquet held in Miami. The Award, unveiled in Frost & Sullivan's
recent analysis, U.S. Rapid Microbiology Test Markets, is a result of Quidel's proven growth, technological innovation and leadership.
Click here for more
information concerning this exciting
press release.
Our Feature Profile:
(NasdaqNM: QDEL)
Company Profile
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit.
Company Web Site:
Click on the links to the various sections covered on the Company's web site:
Key Management:
- Ms. Caren L. Mason, Chief Exec. Officer, President, and Director
- Mr. Paul E. Landers, Chief Financial Officer, Principal Accounting Officer
- Mr. Mark E. Paiz, Chief Operating Officer
- Dr. Thomas J. Foley Ph.D., Chief Technology Officer
- Mr. Robert J. Bujarski, VP — VP and Gen. Counsel
Business Summary:
Quidel Corporation engages in the development, manufacture, and marketing of point-of-care (POC) rapid diagnostic solutions for infectious diseases and reproductive health. Its POC and diagnostic tests include QuickVue, QuickVue+, QuickVue Advance, RapidVue, BlueTest, and Metra. These products provide diagnostic information for acute and chronic conditions that affect women and their family's health. The company offers POC diagnostics for infectious diseases, such as Influenza, Group A Strep, Helicobacter pylori, and Mononucleosis; Reproductive Health, which include Pregnancy, Chlamydia, and Bacterial Vaginosis; and Bone Health and Oncology. Quidel’s products under development include Strep A web, respiratory syncitial virus test, LTF technology platforms, and QuickVue advance pH and amines test. The company incorporates immunoassay, enzymology, biochemistry, and microbiology technology into its diagnostic products. It markets its products to its customers through a network of distributors supported by a direct sales force in the United States, and through distributors and sales agents primarily in Japan, Europe, and Latin America. Quidel sells its products to professionals for use in physician offices, hospitals, clinical laboratories, and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, California.
SEC Filings:
Edgar search results for all of QDEL's recent SEC filings can be found at: http://finance.yahoo.com/q/sec?s=QDEL
Share Structure:
| Exchange and Symbol | NasdaqNM: QDEL |
| Recent Price | $10.48, October 7, 2005 |
| 52-week High - Low | $10.48 (high) - $3.45 (low) |
| Average Volume | 271K |
| Market Capitalization | 344.5M |
| Industry Sector | Diagnostic Substances in the Healthcare Sector |
Latest Press Releases:
Contact Information:
| Quidel Corporation |
| 10165 McKellar Court |
| San Diego, CA 92121 |
| Phone: 800-874-1517 |
| Fax: 858-552-1100 |
| E-mail: ir@quidel.com |
| Web Site: www.quidel.com |
Technical Analysis
Conclusion
Quidel Corporation is a leader in the development, manufacturing, and marketing of point-of-care rapid diagnostic solutions for infectious diseases and reproductive health. The distribution of its products is supported by a sales force that is reaching out not only within the U.S., but Internationally (i.e., Japan, Europe, and Latin America) as well. We believe QDEL is a solid investment opportunity and shows outstanding growth potential. If the Company adheres to its overall plan, and strives for a successful future, investors will be rewarded for having invested in the Company.
Disclaimer and Disclosure
© 2005 StockChartist.com, LLC. All rights reserved. StockChartist.com, LLC is not a Registered Investment Advisor or a Broker / Dealer.All materials presented on our web site and individual reports released to the public are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with trading any stock, there is always a high degree of investment risk and volatility. All investors are cautioned that you may lose all or a portion of your investment if you decide to make a purchase in any profiled company. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
This stock profile/advertisement alert contains or incorporates by reference "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements" within the meaning of the Safe Harbor Clause of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements invoke risk and uncertainties that may cause the Company's actual results to differ materially from such forward-looking statements. Forward looking statements in this action may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or that by statements indicating certain actions “may”, “could”, or “might occur”, and similar expressions which are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, demand for the Company's product both domestically and abroad, the Company's ability to continue to develop its market, the Company's ability to obtain necessary financing, general economic conditions, and other factors that may be more fully described in the company's literature and any periodic filings with the Securities and Exchange Commission.
It should be understood that there is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information on our web site or within our report is only as reliable as the sources they were obtained from. Stockchartist.com, LLC does not hold positions in securities mentioned herein, since that may be regarded as a conflict in interest. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Stockchartist.com, LLC did not receive any form of compensation from any source for its efforts in presenting and disseminating this information to our subscriber database, and posting this report on the Stockchartist.com, LLC web site. Stockchartist.com, LLC will not trade the subject stock at any time.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.
Back to our Home Page